Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGOLDONI, Adriana Leticia
dc.contributor.authorMACIEL JR., Milton
dc.contributor.authorRIGATO, Paula Ordonhez
dc.contributor.authorPIUBELLI, Orlando
dc.contributor.authorBRITO, Cyro Alves de
dc.contributor.authorMELO, Andrea
dc.contributor.authorMARQUES, Ernesto Torres
dc.contributor.authorAUGUST, Joseph Thomas
dc.contributor.authorDUARTE, Alberto Jose da Silva
dc.contributor.authorSATO, Maria Notomi
dc.date.accessioned2017-11-27T16:35:10Z
dc.date.available2017-11-27T16:35:10Z
dc.date.issued2011
dc.description.abstractVaccines capable of inducing mucosal immunity in early postnatal life until adulthood, protecting early sexual initiation, should be considered as strategies to vaccination against HIV. The HIV-1 GAG protein as a chimera with the lysosome-associated membrane protein (LAMP/gag), encoded by a DNA vaccine, is targeted to the endosomal/lysosomal compartment that contains class II MHC molecules and has been shown to be immunogenic in adult mice. Assuming that one such strategy could help to overcome the immunological immaturity in the early postnatal period, we have evaluated the systemic and mucosal immunogenicity of LAMP/gag immunization in neonatal mice. Intranasal immunization with LAMP/gag vaccine induced higher levels of sIgA and IgG anti-GAG antibodies in intestinal washes than did the gag vaccine. The combination of ID injections and the IN protocol with the chimeric vaccine promoted the increase of Ab levels in sera. Both vaccines induced splenic IFN-gamma- secreting cells against GAG peptide pools, as well as in vivo cytotoxic T lymphocyte (CTL) function, and increased the percentage of CD8+ T cells to the immunodominant class I peptide in gut and spleen. However, only the chimeric vaccine was able to enhance Th1/Th2 cytokine secretion in response to class II GAG peptide and to enhance IL-4-secreting cells against GAG peptides and p24 protein stimuli. Long-lasting humoral and cellular responses were detected until adult age, following neonatal immunization with the chimeric vaccine. The LAMP/gag vaccination was able to induce potent GAG-specific T and B cell immune responses in early life which are essential to elicit sustained and long-lasting mucosal and systemic humoral response.
dc.description.indexMEDLINE
dc.description.sponsorshipMinisterio da Saude do Brasil - Programa Nacional de HIV/AIDS/DST [914BRA1101]
dc.description.sponsorshipFAPESP
dc.description.sponsorshipLIM-56/HCFMUSP
dc.identifier.citationIMMUNOBIOLOGY, v.216, n.4, p.505-512, 2011
dc.identifier.doi10.1016/j.imbio.2010.08.007
dc.identifier.issn0171-2985
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23507
dc.language.isoeng
dc.publisherELSEVIER GMBH, URBAN & FISCHER VERLAG
dc.relation.ispartofImmunobiology
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER GMBH, URBAN & FISCHER VERLAG
dc.subjectDNA vaccines
dc.subjectHIV
dc.subjectMice
dc.subjectMucosal
dc.subjectNeonates
dc.subject.othert-cell
dc.subject.othermembrane-protein
dc.subject.othercpg motifs
dc.subject.otherin-vivo
dc.subject.otherintranasal immunization
dc.subject.otherenvelope protein
dc.subject.otherdendritic cells
dc.subject.otherii compartment
dc.subject.otherresponses
dc.subject.otherreceptor
dc.subject.wosImmunology
dc.titleMucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalGOLDONI, Adriana Leticia:Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiency LIM56, BR-05403000 Sao Paulo, Brazil
hcfmusp.author.externalMACIEL JR., Milton:Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA
hcfmusp.author.externalPIUBELLI, Orlando:Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiency LIM56, BR-05403000 Sao Paulo, Brazil
hcfmusp.author.externalMELO, Andrea:Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, Rio De Janeiro, Brazil
hcfmusp.author.externalMARQUES, Ernesto Torres:Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, Rio De Janeiro, Brazil
hcfmusp.author.externalAUGUST, Joseph Thomas:Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA
hcfmusp.citation.scopus14
hcfmusp.contributor.author-fmusphcPAULA ORDONHEZ RIGATO
hcfmusp.contributor.author-fmusphcCYRO ALVES DE BRITO
hcfmusp.contributor.author-fmusphcALBERTO JOSE DA SILVA DUARTE
hcfmusp.contributor.author-fmusphcMARIA NOTOMI SATO
hcfmusp.description.beginpage505
hcfmusp.description.endpage512
hcfmusp.description.issue4
hcfmusp.description.volume216
hcfmusp.origemWOS
hcfmusp.origem.pubmed20870310
hcfmusp.origem.scopus2-s2.0-79952192990
hcfmusp.origem.wosWOS:000289963300009
hcfmusp.publisher.cityJENA
hcfmusp.publisher.countryGERMANY
hcfmusp.relation.referenceAdkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
hcfmusp.relation.referenceCazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3
hcfmusp.relation.referenceDonnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
hcfmusp.relation.referenceRollman E, 2004, GENE THER, V11, P1146, DOI 10.1038/sj.gt.3302275
hcfmusp.relation.referenceHuber S, 2004, J IMMUNOL, V173, P6526
hcfmusp.relation.referenceLambert AA, 2008, BLOOD, V112, P1299, DOI 10.1182/blood-2008-01-136473
hcfmusp.relation.referenceSiegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
hcfmusp.relation.referenceMarques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
hcfmusp.relation.referenceKraynyak KA, 2010, VACCINE, V28, P1942, DOI 10.1016/j.vaccine.2009.10.095
hcfmusp.relation.referenceGrossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
hcfmusp.relation.referenceArruda LB, 2006, J IMMUNOL, V177, P2265
hcfmusp.relation.referenceKojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4
hcfmusp.relation.referenceJiang JQ, 2005, J VIROL, V79, P393, DOI 10.1128/JVI.79.1.393-400.2005
hcfmusp.relation.referenceRuff AL, 1997, J BIOL CHEM, V272, P8671
hcfmusp.relation.referenceMehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
hcfmusp.relation.referenceGerdts V, 2000, NAT MED, V6, P929
hcfmusp.relation.referencede Witte L, 2007, P NATL ACAD SCI USA, V104, P19464, DOI 10.1073/pnas.0703747104
hcfmusp.relation.referenceBessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
hcfmusp.relation.referenceROWELL JF, 1995, J IMMUNOL, V155, P1818
hcfmusp.relation.referenceArthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
hcfmusp.relation.referenceGeijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31
hcfmusp.relation.referenceNeurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567
hcfmusp.relation.referenceAdkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
hcfmusp.relation.referenceBrave A, 2008, VACCINE, V26, P5075, DOI 10.1016/j.vaccine.2008.03.066
hcfmusp.relation.referenceChikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
hcfmusp.relation.referenceDadaglio G, 2002, J IMMUNOL, V168, P2219
hcfmusp.relation.referenceDale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024
hcfmusp.relation.referenceDe Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
hcfmusp.relation.referencede Brito CA, 2009, IMMUNOTHERAPY, V1, P883, DOI [10.2217/imt.09.38, 10.2217/IMT.09.38]
hcfmusp.relation.referenceDeml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037
hcfmusp.relation.referenceGouws E, 2008, AIDS, V22, pS5, DOI 10.1097/01.aids.0000341773.86500.9d
hcfmusp.relation.reference*UNAIDS, 2008, REP GLOB AIDS EP, P1
hcfmusp.relation.referenceValentin A, 2009, VACCINE, V27, P4840, DOI 10.1016/j.vaccine.2009.05.093
hcfmusp.relation.referenceXiang ZQ, 2003, J IMMUNOL, V171, P4287
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication10421ebd-ef5c-4935-950e-ac1032f6d08e
relation.isAuthorOfPublication9213b6fd-954b-494b-9c7e-86e2098b8dd8
relation.isAuthorOfPublication8e4f2c15-06a5-444b-826d-84576403144e
relation.isAuthorOfPublicationc5fbfe7f-eec0-49ea-be33-ce5f13cc3dfb
relation.isAuthorOfPublication.latestForDiscovery10421ebd-ef5c-4935-950e-ac1032f6d08e
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_GOLDONI_Mucosal_and_systemic_antiGAG_immunity_induced_by_neonatal_2011.PDF
Tamanho:
680.37 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56